Clinical Study of Cytomegalovirus Latent Infection in Allogeneic Peripheral Blood Stem Cell Transplantation

Huasheng Liu

2013-01-01

Abstract:Objective:To investigate the clinical effects of prevention and treatment of cytomegalovirus(CMV) latent infection in allogeneic peripheral blood stem cell transplantation(allo-PBSCT)according to the different serologic test results of cytomegalovirus.Method:Thirty-seven patients received allo-PBSCT in First Affiliated Hospital of Xi'an Jiao Tong University between January 2008and October 2012.Their clinical charateristics were analyzed retrospectively.Patients with CMV-IgG positive were given ganciclovir intravenously,while patients with negative CMV PP65antigen and CMV-DNA were given acyclovir for prevention of CMV disease for one week before allo-PBSCT.All patients were given acyclovir during allo-PBSCT.CMV infection was periodically tested.If CMV-PP65antigen,CMV-IgM or CMV-DNA was positive,patients were given ganciclovir or forscarnet sodium with immunoglobin.Result:Thirty-six patients were with positive CMV IgG,seven cases were with positive CMVDNA,and four cases suffered from CMV diseases after allo-PBSCT.The time of CMV infection ranged from twenty seven to sixty five days post transplantation.CMV infection occurred more often in patients with unrelated donors,HLA mismatched donors or aGVHD.No patient died after treatment.There was no difference of hematopoietic reconstruction between patients receiving different anti-CMV treatment.Conclusion:CMV diseases significantly decreased but hematopoietic reconstruction was not affected by preventing and treating CMV latent infection according to different serologic test results in patients undergoing allo-PBSCT.